{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-019073","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2023-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.302479+00:00","generated_at":"2026-06-14T15:00:47.844295+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Indaptus Therapeutics announces 2023 annual meeting voting results; directors elected, auditor ratified","bullets":["4,469,519 shares (~53% of outstanding) represented at May 25, 2023 meeting.","William B. Hayes (2,452,279 for) and Anthony Maddaluna (2,544,652 for) elected as Class II directors.","Ratification of Haskell & White LLP as auditor for FY2023: 4,446,392 for, 22,167 against, 960 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-019073","json":"https://secwatch.observer/filing/0001493152-23-019073.json","markdown":"https://secwatch.observer/filing/0001493152-23-019073.md","text":"https://secwatch.observer/filing/0001493152-23-019073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223019073/0001493152-23-019073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223019073/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T15:00:47.844295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c5374cdb805bfc479e60be2e06107417d890e0af","claim":"Indaptus Therapeutics, Inc. shareholders approved Ratification of the appointment of Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-05-25 meeting.","evidence_excerpt":"Proposal 2. Ratification of the appointment of Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223019073/0001493152-23-019073-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-25"}],"fact_type":"shareholder_vote"},{"claim_id":"d6fb84334d14d7b8cb74e1d7449f3796a3ae2824","claim":"Indaptus Therapeutics, Inc. shareholders approved Election of two Class II directors for a term of office expiring on the date of the annual meeting of stockholders to be held in 2026 and until their respective successors have been duly elected and qualified or until each such director's earlier death, resignation or removal. at the 2023-05-25 meeting.","evidence_excerpt":"Proposal 1 . Election of two Class II directors for a term of office expiring on the date of the annual meeting of stockholders to be held in 2026 and until their respective successors have been duly elected and qualified or until each such director's earlier death, resignation or removal.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223019073/0001493152-23-019073-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-25"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}